At some point in their life, it’s estimated that around 80 per cent of people will be infected with the human papillomavirus (HPV).

Although many infections will go unnoticed, some strains of HPV can damage DNA, leading to various types of cancer, including cervical, anal and oropharyngeal (throat) cancers.

Cervical cancer is the fourth leading cause of cancer deaths in women worldwide, with 88 per cent of cervical cancer cases occurring in low and middle-income countries (LMICs). Fortunately, most cervical cancer is preventable by vaccination.

The development of vaccines against HPV has revolutionised the fight against this virus. Extensive research has demonstrated the high effectiveness of HPV vaccines in preventing infections and subsequent cancers. And yet, as of 2021, only 13 per cent of girls in the world are vaccinated.

Originally, the vaccination regimen recommended two or three doses to provide optimal protection.

However, recent studies have shown the remarkable effectiveness of a single dose, especially for low and middle-income countries (LMICs) where the implementation of multi-dose vaccination programs poses numerous challenges. These include high costs, complex logistics and limited healthcare infrastructure.

Our latest study involving over 800 women in Fiji found the HPV vaccine remained highly effective against the detection of two HPV strains that cause cancer, for up to eight years after vaccination.

The vaccine was 81 per cent effective against the two commonest strains, HPV 16 and 18, that cause about 70 per cent of all cervical cancer cases in Fiji and worldwide.

This approach is also supported by a recent high-quality trial in Kenyan women aged 15-20 years.

The study found that a single dose of the HPV vaccine had a similar efficacy (97.5 per cent) to that of two or three doses at 18 months after vaccination in preventing the detection of HPV types 16 and 18.

Additionally, even in individuals who had previous exposure to HPV, other observational studies have found that a single dose significantly reduced the risk of developing pre-cancerous lesions.

These findings highlight the remarkable potency of a single HPV vaccine dose and its potential to prevent the devastating consequences of HPV-related diseases.

Five observational studies also found that a single dose had similar protection to two or three doses against HPV types 16 and 18, including those from LMIC settings.

The longest follow-up time assessing the effectiveness of a single dose against cervical dysplasia has been 14 years following vaccination. And the longest follow-up time to assess the duration of protection following a single dose against the detection of HPV has been 12 years in a US observational study.

An earlier study by our team in Fiji looked at the immune response in women who had received 0, 1, 2 or 3 doses of vaccine and found that the immune response generated by a single dose of the vaccine can persist for many years, offering prolonged protection against HPV-related diseases.

The duration of protection over a lifetime from a single dose is likely to be similar to two or three doses, given the similar immune response found at 24 months following vaccination found in the Kenyan clinical trial.

The lower cost associated with a single-dose regimen allows for more accessible and affordable vaccination programs, which can have a transformative impact in LMICs. By reducing the number of required doses, the financial burden on healthcare systems and individuals is significantly alleviated.

This affordability enhances the feasibility of nationwide HPV immunisation campaigns and increases vaccine coverage, thereby ensuring a wider reach and greater protection against HPV-related diseases.

Moreover, a single-dose schedule may allow more girls to be vaccinated and women protected given that there is a global HPV vaccine shortage until 2024. The logistical advantages of a single-dose vaccine also simplify the vaccine distribution and administration process.